The Manufacturers Life Insurance Company lowered its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 18.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 221,080 shares of the medical research company’s stock after selling 49,592 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.10% of Edwards Lifesciences Corporation worth $26,139,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Sabal Trust CO lifted its position in Edwards Lifesciences Corporation by 0.5% during the second quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock valued at $347,000 after buying an additional 14 shares during the period. Alps Advisors Inc. lifted its position in Edwards Lifesciences Corporation by 0.3% during the second quarter. Alps Advisors Inc. now owns 5,102 shares of the medical research company’s stock valued at $603,000 after buying an additional 14 shares during the period. Alexandria Capital LLC lifted its position in Edwards Lifesciences Corporation by 1.7% during the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after buying an additional 19 shares during the period. M Holdings Securities Inc. lifted its position in Edwards Lifesciences Corporation by 1.5% during the first quarter. M Holdings Securities Inc. now owns 4,132 shares of the medical research company’s stock valued at $389,000 after buying an additional 62 shares during the period. Finally, Veritable L.P. lifted its position in Edwards Lifesciences Corporation by 1.2% during the second quarter. Veritable L.P. now owns 6,244 shares of the medical research company’s stock valued at $738,000 after buying an additional 71 shares during the period. 82.12% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This report was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/the-manufacturers-life-insurance-company-sells-49592-shares-of-edwards-lifesciences-corporation-ew/1632640.html.

Several brokerages have commented on EW. Canaccord Genuity reissued a “buy” rating and set a $150.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Wednesday, June 28th. Cowen and Company reissued a “buy” rating and set a $135.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Thursday. BidaskClub raised Edwards Lifesciences Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 22nd. Zacks Investment Research lowered Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 17th. Finally, Bank of America Corporation raised their price objective on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, July 27th. Seven analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $120.75.

Shares of Edwards Lifesciences Corporation (NYSE:EW) opened at 108.25 on Friday. The firm’s 50 day moving average price is $111.37 and its 200-day moving average price is $111.44. The company has a market capitalization of $22.86 billion, a P/E ratio of 32.83 and a beta of 0.62. Edwards Lifesciences Corporation has a 1-year low of $81.12 and a 1-year high of $121.45.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.20. The business had revenue of $842.00 million for the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The company’s revenue was up 10.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.76 earnings per share. Analysts expect that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

In other news, VP Donald E. Bobo, Jr. sold 25,000 shares of the stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $116.00, for a total value of $2,900,000.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $114.80, for a total value of $3,776,920.00. The disclosure for this sale can be found here. Insiders sold 182,201 shares of company stock worth $20,768,154 over the last three months. Corporate insiders own 2.13% of the company’s stock.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.